Comparative Evaluation of Emdogain® with Titanium Prepared Platelet-rich Fibrin and Recombinant Human Bone Morphogenetic Protein-2 with Titanium Prepared Platelet-rich Fibrin in the Treatment of Gingival Recession - A Randomized Controlled Trial.

AIM: The present study aims to compare the clinical efficacy of Emdogain® and Recombinant human bone morphogenetic protein-2 (rhBMP-2), adjunctive to Titanium prepared platelet-rich fibrin (T-PRF), in the treatment of gingival recession with the coronally advanced flap (CAF) technique.

SUBJECTS AND

METHODS

The present study is a randomized controlled trial. A Total of 26 patients with gingival recession were assigned randomly into two groups. Group Ⅰ: 13 gingival recession sites with CAF technique, Emdogain®, and T-PRF. Group Ⅱ: 13 gingival recession sites with CAF, rhBMP-2, and T-PRF. The clinical parameters recorded at the baseline and 9 months were recession depth (RD), probing depth (PD), clinical attachment level (CAL), and keratinized tissue width (KTW).

STATISTICAL ANALYSIS: Paired t-test for intragroup differences, Independent samples t-test for intergroup differences, and Levene's test for equality of variances were used.

RESULTS

The clinical parameters like PD, CAL, KTW, and RD in the present trial revealed a significant reduction when compared from baseline to 9 months in both groups. In intragroup comparison, all parameters showed statistical significance (P < 0.005). In intergroup comparison, the KTW improvement was higher in Group Ⅰ when compared to Group Ⅱ.

CONCLUSION

In conclusion, both groups seem to be valuable treatment options for gingival recession. The biomaterials Emdogain®, rhBMP-2, and T-PRF showed promising results in the root coverage procedure.